Cargando…

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?

The dominant theory of Alzheimer disease (AD) has been that amyloid-β (Aβ) accumulation in the brain is the initial cause of the degeneration leading to cognitive and functional deficits. Autosomal dominant Alzheimer disease (ADAD), in which pathologic mutations of the amyloid precursor protein (APP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imbimbo, Bruno P., Lucca, Ugo, Watling, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2020
Materias:	Views & Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862085/ https://www.ncbi.nlm.nih.gov/pubmed/33575481 http://dx.doi.org/10.1212/NXG.0000000000000535

Ejemplares similares

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
por: O'Connor, Antoinette, et al.
Publicado: (2021)

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
por: van Dyck, Christopher H.
Publicado: (2017)

Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer’s disease
por: Levitis, Elizabeth, et al.
Publicado: (2022)

Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Alzheimer Aβ peptide interactions with lipid membranes: Fibrils, oligomers and polymorphic amyloid channels
por: Tofoleanu, Florentina, et al.
Publicado: (2012)

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy revisited: Genotype-phenotype correlations of all published cases
por: Xiromerisiou, Georgia, et al.
Publicado: (2020)

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
por: Weggen, Sascha, et al.
Publicado: (2012)

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
por: Su, Yi, et al.
Publicado: (2016)

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014)

Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer’s disease variants: AβPParc and PSEN1DE9
por: Lemoine, Laetitia, et al.
Publicado: (2020)

Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
por: Guix, Francesc X, et al.
Publicado: (2017)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases
por: LaHue, Sara C., et al.
Publicado: (2020)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

secHsp70 as a tool to approach amyloid-β42 and other extracellular amyloids
por: De Mena, Lorena, et al.
Publicado: (2017)

Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?
por: de Paula, Vanessa de Jesus R., et al.
Publicado: (2009)

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
por: Leisher, Solana, et al.
Publicado: (2023)

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
por: Su, Yi, et al.
Publicado: (2016)

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
por: Norton, Daniel J., et al.
Publicado: (2020)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Chronic liver inflammation dominated by interferon-γ can prevent hepatocarcinogenesis
por: Schrader, Jörg, et al.
Publicado: (2012)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Monoclonal antibody targeting of mononuclear cell chemokines driving malignant pleural effusion
por: Marazioti, Antonia, et al.
Publicado: (2014)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies
por: Rygiel, Katarzyna
Publicado: (2016)

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
por: Tousi, Babak, et al.
Publicado: (2021)

Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
por: Kounis, Nicholas G, et al.
Publicado: (2014)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?
por: Kovacs, Gabor G.
Publicado: (2016)

Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study
por: Sanchez, Justin S., et al.
Publicado: (2021)

First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy
por: Gül, Nuray, et al.
Publicado: (2014)

Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier – phenotypic variability in autosomal dominant Alzheimer’s disease
por: Lloyd, Grace M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4ftjt73to3cnmb4uuhsfc8qdi